Bristol-Meyers Squibb Acquires iPierian for $725,000,000

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f7c4dd2a-fe36-4b09-af87-db77ab5ec6b4
Date
4/29/2014
Company Name
iPierian
Mailing Address
951 Gateway Blvd South San Francisco, CA 94080 USA
Company Description
iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
Website
http://www.ipierian.com
Transaction Type
M&A
Transaction Amount
$725,000,000
Transaction Round
Proceeds Purposes
M&A Terms
Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierian’s issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175 million, with the potential for additional development and regulatory milestone payments totaling $550 million, along with future royalties on net sales.